
MK-1064
CAS No. 1207253-08-4
MK-1064( MK1064 | MK 1064 )
Catalog No. M10761 CAS No. 1207253-08-4
A potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 140 | In Stock |
![]() ![]() |
10MG | 230 | In Stock |
![]() ![]() |
25MG | 455 | In Stock |
![]() ![]() |
50MG | 644 | In Stock |
![]() ![]() |
100MG | 869 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMK-1064
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM.
-
DescriptionA potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM; displays >100-fold selectivity over OX1R; promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats and dogs without inducing cataplexy; also decreases ACTH levels in rats.Sleep Disorder Preclinical(In Vitro):MK-1064 (30?mg/kg, oral administration) promotes sleep in rodents selectively through OX2R in Wild-type mice.MK-1064 (30?mg/kg, oral administration, 5 days) reverses the struggle behavior induced by CNO pre-treatment in rats.MK-1064 (1-5 mg/kg, intravenous injection/oral administration) shows moderate oral bioavailability and clearance in rat, dog, and rhesus monkey.
-
In Vitro——
-
In VivoMK-1064 (30?mg/kg, oral administration) promotes sleep in rodents selectively through OX2R in Wild-type mice.MK-1064 (30?mg/kg, oral administration, 5 days) reverses the struggle behavior induced by CNO pre-treatment in rats.MK-1064 (1-5 mg/kg, intravenous injection/oral administration) shows moderate oral bioavailability and clearance in rat, dog, and rhesus monkey. Animal Model:Wild-type and OX2R knockout miceDosage:30 mg/kg Administration:Oral administration Result:Displayed active wake reduction accompanied by significant increases in SWS (slow-wave sleep) and REM (rapid eye movement) at time points up to 3.5?hours following treatment. Animal Model:Rat, dog, and rhesus monkey (Pharmacokinetics assay)Dosage:1, 2, 3, 5 mg/kg Administration:Oral administration (P.O.), intravenous injection (I.V.)Result:Pharmacokinetics profile of MK-1064.
-
SynonymsMK1064 | MK 1064
-
PathwayGPCR/G Protein
-
TargetOrexin Receptor
-
RecptorOX2
-
Research AreaNeurological Disease
-
IndicationSleep Disorder
Chemical Information
-
CAS Number1207253-08-4
-
Formula Weight461.9003
-
Molecular FormulaC24H20ClN5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(C1=CC(C2=CC(Cl)=CN=C2)=CN=C1C3=NC=CC=C3)NCC4=NC(OC)=C(OC)C=C4
-
Chemical Name[2,2':5',3''-Terpyridine]-3'-carboxamide, 5''-chloro-N-[(5,6-dimethoxy-2-pyridinyl)methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Roecker AJ, et al. ChemMedChem. 2014 Feb;9(2):311-22.
2. Gotter AL, et al. Sci Rep. 2016 Jun 3;6:27147.
3. Grafe LA, et al. Neuroscience. 2017 Apr 21;348:313-323.
molnova catalog



related products
-
Almorexant hydrochlo...
A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively.
-
Seltorexant
A potent, selective, orally active orexin-2 receptor (OX2R) antagonist with pKi of 8.0 and 8.1 for human and rat OX2R, respectively.
-
L-371,257
L-371,257 is a competitive antagonist of oxytocin receptor with pA2 of 8.4 and Ki of 19 nM. L-371,257 shows a Ki of 3.7 nM for vasopressin receptor 1a.